AIDS-related lipodystrophy/insulin resistance syndrome

Tomoshige Kino, M. Mirani, S. Alesci, G. P. Chrousos

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

The recent development and clinical use of three different types of highly effective anti-HIV-1 drugs, including nucleotide and non-nucleotide reverse transcriptase inhibitors (NRTIs) and non-peptidic viral protease inhibitors (Pls) and their combinations, termed highly active antiretroviral therapy (HAART), have dramatically reduced the infection-related mortality of AIDS patients in developed countries. However, the prolongation of the life expectancy of HIV-1-infected patients and/or long-term use of the above antiviral agents have generated a score of new problems and complications. Among them is the relatively common AIDS-related lipodystrophy/insulin resistance syndrome, which is associated with severe metabolic disturbances such as carbohydrate intolerance/diabetes mellitus and severe dyslipidemia, which influence the quality of life and threaten the life expectancies of HIV-1-infected patients by increasing the risk of atherosclerotic cardiovascular disease. The etiology of this syndrome appears to be multi-factorial; the classes of anti-viral drugs listed above, hypercytokinemia in AIDS patients, and the HIV-1 infection itself could induce the pathologic changes of this syndrome or increase the vulnerability of patients to the adverse effect of the therapeutic compounds. In this article, we review our current understanding of the pathogenesis of this severe AIDS-associated metabolic disorder.

Original languageEnglish
Pages (from-to)129-136
Number of pages8
JournalHormone and Metabolic Research
Volume35
Issue number3
DOIs
Publication statusPublished - 1 Mar 2003
Externally publishedYes

Fingerprint

Lipodystrophy
Insulin Resistance
Acquired Immunodeficiency Syndrome
Insulin
HIV-1
Reverse Transcriptase Inhibitors
Medical problems
Protease Inhibitors
Pharmaceutical Preparations
Antiviral Agents
Life Expectancy
Nucleotides
Carbohydrates
Life Support Care
Anti-HIV Agents
Highly Active Antiretroviral Therapy
Therapeutic Uses
Dyslipidemias
Developed Countries
HIV Infections

Keywords

  • Adipose Calls
  • AIDS
  • Fat Distribution
  • Pseudo-Cushing

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

AIDS-related lipodystrophy/insulin resistance syndrome. / Kino, Tomoshige; Mirani, M.; Alesci, S.; Chrousos, G. P.

In: Hormone and Metabolic Research, Vol. 35, No. 3, 01.03.2003, p. 129-136.

Research output: Contribution to journalReview article

Kino, Tomoshige ; Mirani, M. ; Alesci, S. ; Chrousos, G. P. / AIDS-related lipodystrophy/insulin resistance syndrome. In: Hormone and Metabolic Research. 2003 ; Vol. 35, No. 3. pp. 129-136.
@article{d2d89c6e0c0e451ab992543d4f07719f,
title = "AIDS-related lipodystrophy/insulin resistance syndrome",
abstract = "The recent development and clinical use of three different types of highly effective anti-HIV-1 drugs, including nucleotide and non-nucleotide reverse transcriptase inhibitors (NRTIs) and non-peptidic viral protease inhibitors (Pls) and their combinations, termed highly active antiretroviral therapy (HAART), have dramatically reduced the infection-related mortality of AIDS patients in developed countries. However, the prolongation of the life expectancy of HIV-1-infected patients and/or long-term use of the above antiviral agents have generated a score of new problems and complications. Among them is the relatively common AIDS-related lipodystrophy/insulin resistance syndrome, which is associated with severe metabolic disturbances such as carbohydrate intolerance/diabetes mellitus and severe dyslipidemia, which influence the quality of life and threaten the life expectancies of HIV-1-infected patients by increasing the risk of atherosclerotic cardiovascular disease. The etiology of this syndrome appears to be multi-factorial; the classes of anti-viral drugs listed above, hypercytokinemia in AIDS patients, and the HIV-1 infection itself could induce the pathologic changes of this syndrome or increase the vulnerability of patients to the adverse effect of the therapeutic compounds. In this article, we review our current understanding of the pathogenesis of this severe AIDS-associated metabolic disorder.",
keywords = "Adipose Calls, AIDS, Fat Distribution, Pseudo-Cushing",
author = "Tomoshige Kino and M. Mirani and S. Alesci and Chrousos, {G. P.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1055/s-2003-39072",
language = "English",
volume = "35",
pages = "129--136",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "3",

}

TY - JOUR

T1 - AIDS-related lipodystrophy/insulin resistance syndrome

AU - Kino, Tomoshige

AU - Mirani, M.

AU - Alesci, S.

AU - Chrousos, G. P.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - The recent development and clinical use of three different types of highly effective anti-HIV-1 drugs, including nucleotide and non-nucleotide reverse transcriptase inhibitors (NRTIs) and non-peptidic viral protease inhibitors (Pls) and their combinations, termed highly active antiretroviral therapy (HAART), have dramatically reduced the infection-related mortality of AIDS patients in developed countries. However, the prolongation of the life expectancy of HIV-1-infected patients and/or long-term use of the above antiviral agents have generated a score of new problems and complications. Among them is the relatively common AIDS-related lipodystrophy/insulin resistance syndrome, which is associated with severe metabolic disturbances such as carbohydrate intolerance/diabetes mellitus and severe dyslipidemia, which influence the quality of life and threaten the life expectancies of HIV-1-infected patients by increasing the risk of atherosclerotic cardiovascular disease. The etiology of this syndrome appears to be multi-factorial; the classes of anti-viral drugs listed above, hypercytokinemia in AIDS patients, and the HIV-1 infection itself could induce the pathologic changes of this syndrome or increase the vulnerability of patients to the adverse effect of the therapeutic compounds. In this article, we review our current understanding of the pathogenesis of this severe AIDS-associated metabolic disorder.

AB - The recent development and clinical use of three different types of highly effective anti-HIV-1 drugs, including nucleotide and non-nucleotide reverse transcriptase inhibitors (NRTIs) and non-peptidic viral protease inhibitors (Pls) and their combinations, termed highly active antiretroviral therapy (HAART), have dramatically reduced the infection-related mortality of AIDS patients in developed countries. However, the prolongation of the life expectancy of HIV-1-infected patients and/or long-term use of the above antiviral agents have generated a score of new problems and complications. Among them is the relatively common AIDS-related lipodystrophy/insulin resistance syndrome, which is associated with severe metabolic disturbances such as carbohydrate intolerance/diabetes mellitus and severe dyslipidemia, which influence the quality of life and threaten the life expectancies of HIV-1-infected patients by increasing the risk of atherosclerotic cardiovascular disease. The etiology of this syndrome appears to be multi-factorial; the classes of anti-viral drugs listed above, hypercytokinemia in AIDS patients, and the HIV-1 infection itself could induce the pathologic changes of this syndrome or increase the vulnerability of patients to the adverse effect of the therapeutic compounds. In this article, we review our current understanding of the pathogenesis of this severe AIDS-associated metabolic disorder.

KW - Adipose Calls

KW - AIDS

KW - Fat Distribution

KW - Pseudo-Cushing

UR - http://www.scopus.com/inward/record.url?scp=0037617482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037617482&partnerID=8YFLogxK

U2 - 10.1055/s-2003-39072

DO - 10.1055/s-2003-39072

M3 - Review article

VL - 35

SP - 129

EP - 136

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 3

ER -